Scientific Opinion on the substantiation of a health claim related to oat beta glucan and lowering blood cholesterol and reduced risk of (coronary) heart disease pursuant to Article 14 of Regulation (EC) No 1924/2006

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA),

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)

Search for more papers by this author

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA),

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)

Search for more papers by this author

First published: 08 December 2010

https://doi.org/10.2903/j.efsa.2010.1885

Citations: 41

Panel members: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, Hendrik van Loveren and Hans Verhagen.

Correspondence: [email protected]

Acknowledgement: The Panel wishes to thank Mariette Gerber, Antti Aro and the members of the Working Group on Claims: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Marina Heinonen, Hannu Korhonen, Martinus Løvik, Ambroise Martin, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Inge Tetens, Hendrik van Loveren and Hans Verhagen for the preparatory work on this scientific opinion.

Adoption date: 12 November 2010

Published date: 8 December 2010

Question number: EFSA-Q-2008-681

On request from: Competent Authority of the United Kingdom following an application by CreaNutrition AG

About

PDF

Tools

Share a link

Email
Facebook
Twitter
LinkedIn
Reddit
Wechat

Abstract

Following an application from CreaNutrition AG submitted pursuant to Article 14 of Regulation (EC) No 1924/2006 via the Competent Authority of the United Kingdom, the Panel on Dietetic Products, Nutrition and Allergies was asked to deliver an opinion on the scientific substantiation of a health claim related to oat beta glucan and lowering of blood LDL and total cholesterol. Oat beta-glucan is sufficiently characterised. Lowering blood LDL-cholesterol concentrations is a beneficial physiological effect by decreasing the risk of coronary heart disease. The applicant identified a total of 22 references, which included three meta-analyses and 19 randomised controlled trials, as being pertinent to the health claim. In weighing the evidence, the Panel took into account that most of the trials investigating the effects of oat beta-glucan at doses of at least 3 g/d have shown a statistically significant decrease in LDL-cholesterol concentrations, and that there was strong evidence supporting the biological plausibility of the effect. The Panel concludes that a cause and effect relationship has been established between the consumption of oat beta-glucan and lowering of blood LDL-cholesterol concentrations. The following wording reflects the scientific evidence: “Oat beta-glucan has been shown to lower/reduce blood cholesterol. Blood cholesterol lowering may reduce the risk of (coronary) heart disease”. The Panel considers that, in order to bear the claim, foods should provide at least 3 g of oat beta-glucan per day. This amount can reasonably be consumed as part of a balanced diet. The target population is adults who want to lower their blood cholesterol concentrations.

References

AFSSA (Agence française de sécurité sanitaire des aliments), 2008. Opinion on an application for assessment of the scientific basis of a claim relating to the effect on bloodstream cholesterol of soluble oat fibres consumed as part of an adjusted diet. Referral No. 2007-SWA-0168. Available from www.affsa.fr.

Google Scholar
Amundsen AL, Haugum B and Andersson H, 2003. Changes in blood cholesterol and sterol metabolites after intake of products enriched with oat bran concentrate within a controlled diet. Scandinavian Journal of Nutrition, 47, 68–74.
10.1080/11026480310009573
Google Scholar
Berg A, Konig D, Deibert P, Grathwohl D, Berg A, Baumstark MW and Franz IW, 2003. Effect of an oat bran enriched diet on the atherogenic lipid profile in patients with an increased coronary heart disease risk. A controlled randomized lifestyle intervention study. Annals of Nutrition and Metabolism, 47, 306–311.
10.1159/000072404
CASPubMedWeb of Science®Google Scholar
Braaten JT, Wood PJ, Scott FW, Wolynetz MS, Lowe MK, Bradley-White P and Collins MW, 1994. Oat ß-glucan reduces blood cholesterol concentration in hypercholesterolemic subjects. European Journal of Nutrition, 48, 465–474.

PubMedWeb of Science®Google Scholar
Brown L, Rosner B, Willett WW and Sacks FM, 1999. Cholesterol-lowering effects of dietary fibre: a meta-analysis. American Journal of Clinical Nutrition, 69, 30–42.
10.1093/ajcn/69.1.30
CASPubMedWeb of Science®Google Scholar
Ministry for Health of the Czech Republic, 2005. Assessment Report on beta-glucan containing bread, 28.06.2005.

Google Scholar
Davy BM, Davy KP, Ho RC, Beske SD, Davrath LR and Melby CL, 2002. High-fibre oat cereal compared with wheat cereal consumption favorably alters LDL cholesterol subclass and particle numbers in middle-aged and older men. American Journal of Clinical Nutrition, 76, 351–358.
10.1093/ajcn/76.2.351
CASPubMedWeb of Science®Google Scholar
Denke MA, 2005. Diet, lifestyle, and nonstatin trials: review of time to benefit. American Journal of Cardiology, 96, 3–10.
10.1016/j.amjcard.2005.06.014
CASPubMedWeb of Science®Google Scholar
Donazzolo Y, Latreille-Barbier M, Ruel C, Laure S, Alken R and Macmahon M, 2006 (unpublished, proprietary data). Effect of a combination of oat bran and soy germ and oat bran and soy germ alone on cholesterol metabolism in mildly hypercholesterolemic subjects: an international multicentre randomised study.

Google Scholar
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2009. Scientific Opinion on the substantiation of health claims related to beta-glucans and maintenance of normal blood cholesterol concentrations (ID 754, 755, 757, 801, 1465, 2934) and maintenance or achievement of a normal body weight (ID 820, 823) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal, 7(9): 1254, 18 pp.
10.2903/j.efsa.2009.1254
Google Scholar
FDA (US Food and Drug Administration), 1997. Food Labeling: Health Claims. Soluble Fiber From Whole Oats and Risk of Coronary Heart Disease. Docket No. 95P-0197.

Google Scholar
FDA (US Food and Drug Administration), 2003. Food Labeling: Health Claims. Soluble Dietary Fiber From Certain Foods and Coronary Heart Disease. Docket No. 2001Q-0313.

Google Scholar
Frid A, Hofstedt A, Granfeldt Y, Nyberg L and Björck I, 2007 (unpublished, proprietary data). On the effect of a ß-glucan enriched oat muesli on blood lipids in healthy subjects with first-degree heredity for type 2 diabetes.

Google Scholar
Gerhardt AL and Gallo NB, 1998. Full-fat rice bran and oat bran similarly reduce hypercholesterolemia in humans. Journal of Nutrition, 128, 865–869.
10.1093/jn/128.5.865
CASPubMedWeb of Science®Google Scholar
Gordon DJ, 2000. Cholesterol lowering reduces mortality. The Statins. In: Cholesterol-Lowering Therapy. Evaluation of Clinical Trial Evidence. Ed SM. GrundyMarcel Dekker Inc., 299–311.

Google Scholar
JHCI (Joint Health Claims Initiative), 2006. Generic Claims - oats and reduction of blood cholesterol. Available from www.jhci.org.uk/approv/oats.htm.

Google Scholar
Kabir M, Oppert JM, Vidal H, Bruzzo F, Fiquet C, Wursch P, Slama G and Rizkalla SW, 2002. Four-week low-glycemic index breakfast with a modest amount of soluble fibers in Type 2 diabetic men. Metabolism, 51, 819–826.
10.1053/meta.2002.33345
CASPubMedWeb of Science®Google Scholar
Karmally W, Montez MG, Palmas W, Martinez W, Branstetter A, Ramakrishnan R, Holleran SF, Haffner SM and Ginsberg HN, 2005. Cholesterol-lowering benefits of oat-containing cereal in Hispanic Americans. Journal of the American Dietetic Association, 105, 967–970.
10.1016/j.jada.2005.03.006
CASPubMedWeb of Science®Google Scholar
Kerckhoffs DA, Hornstra G and Mensink RP, 2003. Cholesterol-lowering effect of ß-glucan from oat bran in mildly hypercholesterolaemic subjects may decrease when ß-glucan is incorporated into bread and cookies. American Journal of Clinical Nutrition, 78, 221–227.
10.1093/ajcn/78.2.221
CASPubMedWeb of Science®Google Scholar
Lovegrove JA, Clohessy A, Milon H and Williams CM, 2000. Modest doses of ß-glucan do not reduce concentrations of potentially atherogenic lipoproteins. American Journal of Clinical Nutrition, 72, 49–55.
10.1093/ajcn/72.1.49
CASPubMedWeb of Science®Google Scholar
Mensink R, Verkooijen I, Breedveld-Peters J, Van Osch L, Bouts L, Jorristma-Simons G and Brummer RJ, 2005 (unpublished, proprietary data). The effect of daily consumption for three weeks of 140 g (4 slices) of Pró -FIT® bread, containing 2.2 g ß-glucan from OatWell® oat bran per 100 g bread, on the serum concentration of low-density lipoprotein (LDL) cholesterol in hypercholesterolemic subjects.

Google Scholar
Naumann E, Van Rees AB, Önning G, Oste R, Wydra M and Mensink RP, 2006. ß-Glucan incorporated into a fruit drink effectively lowers serum LDL-cholesterol concentrations. American Journal of Clinical Nutrition, 83, 601–605.
10.1093/ajcn.83.3.601
CASPubMedWeb of Science®Google Scholar
Netherlands Voedingscentrum, 2005. Assessment Report, 19-04-05, on Pró-FIT® bread, containing 2.2 g ß-glucan from OatWell® oat bran per 100 g bread.

Google Scholar
Netherlands Voedingscentrum, 2007. Assessment Report, 26-3-2007, on ten different types of OatWell® bread containing 3 g oat β-glucan (from OatWell® oat bran) per daily portion.

Google Scholar
Netherlands Voedingscentrum, 2008. Assessment Report, 25-1-2008, on four different types of OatWell® cereal products providing 3 g oat ß-glucan (from OatWell® oat bran per day).

Google Scholar
Önning G, Wallmark A, Persson M, Akesson B, Elmstahl S and Oste R, 1999. Consumption of oat milk for 5 weeks lowers blood cholesterol and LDL cholesterol in free-living men with moderate hypercholesterolaemia. Annals of Nutrition and Metabolism, 43, 301–309.
10.1159/000012798
CASPubMedWeb of Science®Google Scholar
Ornish D, Scherwitz LW, Billings JH, Brown SE, Gould KL, Merritt TA, Sparler S, Armstrong WT, Ports TA, Kirkeeide RL, Hogeboom C and Brand RJ, 1998, erratum in 1999. Intensive lifestyle changes for reversal of coronary heart disease. Journal of the American Medical Association, 280, 2001–2007, erratum 281, 1380.

PubMedGoogle Scholar
Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M and Tsai J, 2005. Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. Journal of the American Medical Association, 294, 2437–2445.
10.1001/jama.294.19.2437
CASPubMedWeb of Science®Google Scholar
Pick ME, Hawrysh ZJ, Gee MI, Toth E, Garg ML and Hardin RT, 1996. Oat bran concentrate bread products improve long-term control of diabetes: a pilot study. Journal of the American Dietetic Association, 96, 1254–1261.
10.1016/S0002-8223(96)00329-X
PubMedWeb of Science®Google Scholar
Pins JJ, Geleva D, Keenan JM, Frazel C, O'Connor PJ and Cherney LM, 2002. Do whole-grain oat cereals reduce the need for antihypertensive medications and improve blood pressure control? The Journal of Family Practice, 51, 353–359.

PubMedWeb of Science®Google Scholar
Queenan KM, Stewart ML, Smith KN, Thomas W, Fulcher G and Slavin JL, 2007. Concentrated oat ß-glucan, a fermentable fiber, lowers serum cholesterol in hypercholesterolemic adults in a randomized controlled trial. Nutrition Journal, 6, 6.
10.1186/1475-2891-6-6
CASPubMedWeb of Science®Google Scholar
Ripsin CM, Keenan JM, Jacobs DR Jr, Elmer PJ, Welch RR, Van Horn L, Liu K, Turnbull WH, Thye FW and Kestin M, 1992. Oat products and lipid lowering. A meta-analysis. The Journal of the American Medical Association, 267, 3317–3325.

CASPubMedWeb of Science®Google Scholar
Saltzman E, Das SK, Lichtenstein AH, Dallal GE, Corrales A, Schaefer EJ, Greenberg AS and Roberts SB, 2001. An oat-containing hypocaloric diet reduces systolic blood pressure and improves lipid profile beyond effects of weight loss in men and women. Journal of Nutrition, 131, 1465–1470.
10.1093/jn/131.5.1465
CASPubMedWeb of Science®Google Scholar
Swedish Nutrition Foundation, 2004. The Swedish Code - Reduction of disease risk claims. Available from www.snf.ideon.se/snf/en/rh/Generic_claims.htm.

Google Scholar
Swedish Nutrition Foundation, 2007. Primaliv, muesli products (with beta-glucans) and “lowers blood cholesterol levels”. Available from www.snf.ideon.se/snf/en/rh/pfp/primalivmuesli.htm.

Google Scholar
Swiss Federal Office of Public Health, 2006. Available from www.bag.admin.ch/index.html?lang=gn.

Google Scholar
Theuwissen E and Mensink RP, 2007. Simultaneous Intake of β-Glucan and Plant Stanol Esters Affects Lipid Metabolism in Slightly Hypercholesterolemic Subjects. Journal of Nutrition, 137, 583–588.
10.1093/jn/137.3.583
CASPubMedWeb of Science®Google Scholar
Tosh SM, Brummer Y, Miller SS, Regand A, Defelice C, Duss R, Wolever TMS and Wood PJ, 2010. Processing affects the physicochemical properties of ß-glucan in oat bran cereal. Journal of Agricultural and Food Chemistry, 58, 7723–7730.
10.1021/jf904553u
CASPubMedWeb of Science®Google Scholar
Van Horn L, McCoin M, Kris-Etherton PM, Burke F, Carson JA, Champagne CM, Karmally W and Sikand G, 2008. The evidence for dietary prevention and treatment of cardiovascular disease. Journal of the American Dietetic Association, 108, 287–331.
10.1016/j.jada.2007.10.050
CASPubMedWeb of Science®Google Scholar
Whitehead A, 2008 (unpublished, proprietary data). Meta-analysis to quantify the effects of oat beta-glucan on cholesterol. MPS Research Unit, Department of Mathematics and Statistics, Lancaster University, UK.

Google Scholar
WHO (World Health Organization), 2002a. Diet, nutrition and the prevention of chronic diseases. Report of a Joint WHO/FAO expert consultation, Geneva 28 January-1 February 2002. WHO Technical Report Series 916.

Google Scholar
WHO (World Health Organisation), 2002b. The World Health Report 2002 - Reducing Risks, Promoting Healthy Life. Available from www.who.int/whr/2002/en/.

Google Scholar
Wolever TMS, Tosh SM, Gibbs AL, Brand-Miller J, Duncan AM, Hart V, Lamarche B, Thomson BA, Duss R and Wood PJ, 2010. Physicochemical properties of oat ß-glucan influence its ability to reduce serum LDL cholesterol in humans: a randomized clinical trial. American Journal of Clinical Nutrition, 92, 723–732.
10.3945/ajcn.2010.29174
CASPubMedWeb of Science®Google Scholar
Wood PJ, Beer MU and Butler G, 2000. Evaluation of role of concentration and molecular weight of oat β-glucan in determining effect of viscosity on plasma glucose and insulin following an oral glucose lead. British Journal of Nutrition, 84, 19–23.

CASGoogle Scholar

Citing Literature

Volume8, Issue12

December 2010

1885

Scientific Opinion on the substantiation of a health claim related to oat beta glucan and lowering blood cholesterol and reduced risk of (coronary) heart disease pursuant to Article 14 of Regulation (EC) No 1924/2006

Abstract

References

Citing Literature

References

Information

RESOURCES

PUBLICATION INFO

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Scientific Opinion on the substantiation of a health claim related to oat beta glucan and lowering blood cholesterol and reduced risk of (coronary) heart disease pursuant to Article 14 of Regulation (EC) No 1924/2006

Abstract

References

Citing Literature

References

Related

Information

RESOURCES

PUBLICATION INFO